Livzon Pharmaceutical Group Inc. (HKG:1513)

Market Cap	30.85B +5.3%
Revenue (ttm)	13.38B +1.8%
Net Income	2.25B -1.8%
EPS	2.52 +1.2%
Shares Out	n/a
PE Ratio	13.70
Forward PE	12.03
Dividend	1.20 (4.52%)
Ex-Dividend Date	Jun 13, 2025

Volume	905,200
Average Volume	864,869
Open	26.50
Previous Close	26.50
Day's Range	26.50 - 27.30
52-Week Range	24.85 - 41.85
Beta	0.37
RSI	42.17
Earnings Date	Mar 24, 2026

About HKG:1513

Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients (API) and intermediates in the People’s Republic of China and internationally. The company offers leuprorelin acetate microspheres, urofollitropin, and menotropins for injection for the assisted reproduction field; Ilaprazole enteric-coated tablets, ilaprazole sodium for injection, and bismuth potassium citrate products for the gastrointestinal field; fluvoxamine maleate for the psychiatric and neuro...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1985
• Employees: 8,878
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1513

Financial Performance

In 2025, HKG:1513's revenue was 12.02 billion, an increase of 1.76% compared to the previous year's 11.81 billion. Earnings were 2.02 billion, a decrease of -1.84%.

Financial numbers in CNY